Blair Burnett

Blair Burnett supports clients with research and analysis that span a variety of healthcare sectors and stakeholders.

With experience in provider associations, management consulting, and advocacy groups, she assists clients with analysis on a range of federal health policy topics. Blair has particular expertise in policy issues related to oncology and Medicare Part B.

Prior to joining Avalere, Blair was senior policy analyst at the Association of Community Cancer Centers where she oversaw the legislative and regulatory advocacy priorities at the federal and state level for over 2,500 cancer care programs in the association’s membership. Prior to that, Blair was a healthcare analyst with Huron Consulting Group where she assisted clients in care access and revenue cycle projects.

Blair has a BA in public policy with a minor in information science from the University of North Carolina at Chapel Hill.

Authored Content

New Avalere analysis finds that the latest version of Medicare negotiation in the Build Back Better Act (BBBA) would lead to a 40% cut on average for Medicare providers that furnish the Part B drugs that are likely to be initially targeted for negotiation.

In this episode of Avalere Health Essential Voice Journal Club Review, our experts discuss the findings, themes, and relevant application of a study on the impact of Medicaid expansion on coverage and care for women of reproductive age.

An Avalere analysis found that the impact of removing low-risk/low-intensity episodes from the Oncology Care Model (OCM) reconciliation process would not have a notable impact for most practices. Among practices where performance would change, however, performance would improve for most practices if enrolled in 1-sided risk but worsen for most practices if enrolled in alternative 2-sided risk.

Beginning July 1, 2021, average sales price (ASP) calculations for Part B drugs with an additional non-covered self-administered formulation could alter Medicare reimbursement.

On March 8–9, the Presidential Advisory Council on HIV/AIDS (PACHA) discussed avenues to achieving equitable access to HIV prevention products for at-risk populations as well as next steps in revising the National Strategic Plan to End the HIV Epidemic.

As the Oncology Care Model (OCM) approaches its conclusion, stakeholders are anxiously awaiting the details of the Center for Medicare & Medicaid Innovation's (CMMI’s) next oncology episodic payment model, Oncology Care First (OCF).

Amid the continuing pandemic and calls for healthcare reform, the new administration seeks to confront the myriad public health issues facing our country today.

New Avalere analysis finds that the the Most Favored Nation (MFN) Model would have a significant negative impact on Medicare providers that furnish Part B drugs—especially in oncology and rheumatology—and those in rural areas.

New Avalere analysis finds that most Medicare fee-for-service (FFS) beneficiaries would not see a substantial reduction in their out-of-pocket (OOP) costs as a result of the Most Favored Nation (MFN) model.

The November 2020 election is widely anticipated to have important implications for how the US responds to COVID-19.

New Avalere analysis finds that practices currently participating in the Oncology Care Model (OCM) would be more likely to receive a Novel Therapy Adjustment (NTA) in the newly proposed Oncology Care First (OCF) Model.